Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)
Philip Connor, Mayte Sanchez van Kammen, Anthonie WA Lensing, Elizabeth Chalmers, Krisztian Kallay, Kerry Hege, Paolo Simioni, Tina Biss, Fanny Bajolle, Damien Bonnet, Sebastian Grunt, Riten Kumar, Olga Lvova, Rukhmi Bhat, An Van Damme, Joseph Palumbo, Amparo Santamaria, Paola Saracco, Jeanette Payne, Susan Baird Show all
BLOOD ADVANCES | AMER SOC HEMATOLOGY | Published : 2020
Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebral venous thrombosis (CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued on heparin or switched to vitamin K antagonist). The main treatment period was 3 months. The primary efficacy outcome, symptomatic recurrent venous thromboembolism (VTE), and principal safety outcome, major or clinically relevant nonmajor bleeding,were..View full abstract
This study was supported by Bayer AG and Janssen Research and Development.